Covid-19 roundup: Tiny sample size leads FDA to turn down Rigel's EUA; Seattle biotech to co-develop mRNA vaccine in South Korea
Four months after Rigel announced possible Phase II results for its Covid-19 treatment, the FDA has deemed the sample size too small and insufficient for an emergency use authorization, the company announced Friday.
The Phase II trial of fostamatinib, which has previously been approved by the FDA as a second-line therapy for thrombocytopenia, treated just 59 patients. Right now, a larger Phase III trial in hospitalized patients is underway to examine the efficacy of fostamatinib in hospitalized patients with mild-to-severe Covid-19 complications.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.